PNC-27 Product Description
PNC-27 is a synthetic peptide designed to selectively kill cancer cells by targeting a protein called HDM-2 (also known as MDM2) found on the membranes of many cancer cells. It works by binding to membrane-bound HDM-2, forming pores in the cancer cell membrane, and causing rapid cell death through necrosis, while sparing normal cells.
PNC-27 is derived from the p53 proteinโs HDM-2 binding domain (amino acids 12-26) and is linked to a membrane-penetrating sequence, allowing it to enter and act on cancer cellย membranes. The peptide binds specifically to HDM-2 present on the surface of cancer cells, not normal cells. This binding leads to the formation of transmembrane pores, disrupting the cell membrane and causing cell lysis and necrosis, independent of the p53ย pathway.
Peptide Information
| Property |
Value |
| Peptide Sequence |
Pro-Pro-Leu-Ser-Gln-Glu-Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu-Lys-Lys-Trp-Lys-Met-Arg-Arg-Asn-Gln-Phe-Trp-Val-Lys-Val-Gln-Arg-Gly |
| Molecular Formula |
C188H293N53O44S |
| Molecular Weight |
4029.2 g/mol |
| CAS Number |
1159861-00-3 |
| Synonyms |
H-PPLSQETFSDLWKLLKKWKMRRNQFWVKVQRG-OH, PPLSQETFSDLWKLLKKWKMRRNQFWVKVQRG-acid, H-Pro-Pro-Leu-Ser-Gln-Glu-Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu-Lys-Lys-Trp-Lys-Met-Arg-Arg-Asn-Gln-Phe-Trp-Val-Lys-Val-Gln-Arg-Gly-OH, A6, Paralit |
PNC-27ย Peptide Structure
Source: PubChem
Lyophilized Peptides:
These peptides are freeze-dried, a process that not only extends shelf life but also preserves the purity and integrity of the peptides during storage. We do not use any fillers in this process.
PNC-27 targets cancer cells because they express high levels of membrane-bound HDM-2, unlike normal cells, which have little or none. This selectivity results in minimal toxicity to normal cells, including hematopoietic stem cells and other non-cancerous tissues.[1]
Broad Anticancer Activity
PNC-27 has demonstrated cytotoxicity against a wide range of solid and hematopoietic tumors, including chemotherapy-resistant cancers and primary tumor cells from ovarian and uterine cancers. The anticancer peptide has also shown efficacy in animal models, eradicating metastatic pancreatic tumors and leukemia stem cells. [1][2][3]
Primary Tumor Studies
Ex vivo studies on freshly isolated primary human ovarian and uterine cancer cells confirmed that PNC-27 induces dose-dependent cell death, with no observed effect on normal cells.[2]
References
- Pincus, M., Silberstein, M., Zohar, N., SarafrazโYazdi, E., & Bowne, W. (2024). Poptosis or Peptide-Induced Transmembrane Pore Formation: A Novel Way to Kill Cancer Cells without Affecting Normal Cells.ย Biomedicines, 12.ย https://doi.org/10.3390/biomedicines12061144.
- SarafrazโYazdi, E., Salame, G., Gorelick, C., Wagreich, A., Angert, M., Abulafia, O., Pincus, M., & Michl, J. (2011). Abstract C44: Ex vivo cytotoxicity of PNC-27 on primary human ovarian and endometrial cancers.ย Cancer Research, 71.ย https://doi.org/10.1158/1538-7445.FBCR11-C44.
- Wang, H., Zhao, D., Nguyen, L., Wu, H., Li, L., Dong, D., Troadec, E., Zhu, Y., Hoang, D., Stein, A., Malki, M., Aldoss, I., Lin, A., Ghoda, L., McDonald, T., Pichiorri, F., Carlesso, N., Kuo, Y., Zhang, B., Jin, J., & Marcucci, G. (2019). Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia.ย Leukemia, 34, 75-86.ย https://doi.org/10.1038/s41375-019-0522-9.
